Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?
Michele AquilanoMauro LoiLuca VisaniLorenzo LiviJoost J NuyttensPublished in: Acta oncologica (Stockholm, Sweden) (2023)
Median DFS was 7 months, translating into the continuation of effective systemic treatment as other metastases grow slowly. In patients with oligoprogression disease, SBRT is a valid and efficient treatment that may enable postponing the switch of systemic line.